Tamoxifen as a therapeutic agent in acromegaly

Pituitary

Volumn 17, Issue 6, 2014, Pages 500-504

  Balili, Irida ^a   Barkan, Ariel ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Estrogen; Growth hormone; IGF 1

Indexed keywords

CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; TAMOXIFEN; TESTOSTERONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HUMAN GROWTH HORMONE;

ACROMEGALY; ADULT; AGED; ARTICLE; BREAST TENDERNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SCREENING; DRUG TOLERABILITY; DRUG USE; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; GYNECOMASTIA; HUMAN; MALE; MIDDLE AGED; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SEX HORMONE DETERMINATION; SEXUAL DYSFUNCTION; SOMATOMEDIN C BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; BLOOD; CASE REPORT; METABOLISM; TREATMENT OUTCOME; YOUNG ADULT;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; TAMOXIFEN; TESTOSTERONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84911997973     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0534-9     Document Type: Article

References (22)

1. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Acromegaly consensus group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509–1517
2. Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93:2957–2968
3. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D (1998) Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139:516–521
4. Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Bru¨bach K, Stalla GK, Strasburger CJ (2009) German pegvisomant observational study. The German ACROSTUDY: past and present. Eur J Endocrinol 161(Suppl 1):S3–S10
5. Albright F, Reifenstein EG Jr et al (1946) Effect of estrogens in acromegaly. Trans Conf Metab Asp Conval 12–13:102–122
6. McCullagh EP, Beck JC, Schaffenburg CA (1955) Control of diabetes and other features of acromegaly following treatment with estrogens. Diabetes 4:13–23
7. Mintz DH, Finster JL, Josimovich JB (1967) Effect of estrogen therapy on carbohydrate metabolism in acromegaly. J Clin Endocrinol Metab 27:1321–1327
8. Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25:693–721
9. Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, Leong GM, Ross RJ, Ho KK (2003) Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA 100:1016–1021
10. Fournier B, Gutzwiller S, Dittmar T, Matthias G, Steenbergh P, Matthias P (2001) Estrogen receptor (ER)-alpha, but not ER-beta, mediates regulation of the insulin-like growth factor I gene by antiestrogens. J Biol Chem 276:35444–35449
11. Cozzi R, Attanasio R, Oppizzi G, Orlandi P, Giustina A, Lodrini S, Da Re N, Dallabonzana D (1997) Effects of tamoxifen on GH and IGF-I levels in acromegaly. J Endocrinol Invest 20:445–451
12. Metzger DL, Kerrigan JR (1994) Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of endogenous estrogens during male adolescence. J Clin Endocrinol Metab 79:513–518
13. Lahti EI, Knip M, Laatikainen TJ (1994) Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer 74:618–624
14. Corsello SM, Rota CA, Putignano P, Della Casa S, Barnabei A, Migneco MG et al (1998) Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer. Eur J Endocrinol 139:309–313
15. Ho GH, Ji CY, Phang BH, Lee KO, Soo KC, Ng EH (1998) Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: a prospective paired cohort study. Ann Surg Oncol 5:361–367
16. Shupnik MA, Pitt LK, Soh AY, Anderson A, Lopes MB, Laws ER Jr (1998) Selective expression of estrogen receptor alpha and beta isoforms in human pituitary tumors. J Clin Endocrinol Metab 83:3965–3972
17. Chaidarun SS, Swearingen B, Alexander JM (1998) Differential expression of estrogen receptor-beta (ERbeta) in human pituitary tumors: functional interactions with ER alpha and a tumorspecific splice variant. J Clin Endocrinol Metab 83:3308–3315
18. Jaffe CA, Pan W, Brown MB, DeMott-Friberg R, Barkan AL (2001) Regulation of GH secretion in acromegaly: reproducibility of daily GH profiles and attenuated negative feedback by IGF-I. J Clin Endocrinol Metab 86:4364–4370
19. Manolopoulou J, Alami Y, Petersenn S, Schopohl J, Wu Z, Strasburger CJ, Bidlingmaier M (2012) Automated 22-kD growth hormone-specific assay without interference from Pegvisomant. Clin Chem 58(10):1446–1456
20. Bajuk Studen K, Barkan A (2008) Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models. J Clin Endocrinol Metab 93(2):491–496
21. Dimaraki EV, Symons KV, Barkan AL (2004) Raloxifene decreases serum IGF-1 in male patients with active acromegaly. Eur J Endocrinol 150(4):481–487
22. Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96(5):1327–1335